Company intelligence / Profile preview
Xi'an Aolitai Pharmaceutical Technology
Xi'an, Shaanxi Sheng/Shaanxi Province, Chinaxaalt.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xi'an Aolitai Pharmaceutical Technology is developing MT2004, a novel synthetic small molecule FXR agonist for the treatment of cholestatic and mixed drug-induced liver injury. The company has advanced MT2004 into Phase 2 clinical trials, with previous completion of a Phase 1 study. The ongoing multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate safety and efficacy in DILI subjects[4][10].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule drugSynthetic small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Xi'an Aolitai Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xi'an Aolitai Pharmaceutical Technology.